Evogene Reports Second Quarter 2024 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2024
0mins
Should l Buy EVGN?
Source: PRnewswire
Financial Performance: Evogene Ltd. reported significant revenue growth in H1 2024, reaching $5.1 million compared to $1.3 million in H1 2023, while reducing its net loss to $9.8 million from $14.8 million year-over-year. The company anticipates continued revenue growth driven by seed orders totaling over $8 million.
Subsidiary Developments: Casterra Ag secured a $440K order for castor seeds and completed a successful harvest season in Brazil, while Lavie Bio expanded its bio-inoculant product line and Biomica presented promising clinical results for its microbiome-based therapeutics at ASCO 2024.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVGN
Wall Street analysts forecast EVGN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.768
Low
2.50
Averages
2.50
High
2.50
Current: 0.768
Low
2.50
Averages
2.50
High
2.50
About EVGN
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evogene to Present at BIO-Europe Spring 2026 Conference
- Conference Appearance: Evogene Ltd. will present at the BIO-Europe Spring 2026 conference in Lisbon, Portugal, from March 23-25, showcasing its latest achievements in the pharma division, which is expected to attract industry attention and enhance the company's visibility.
- Technology Breakthrough Presentation: Chief Development Officer Dr. Gabi Tarcic and VP of Business Development Dr. Olga Nissan will highlight AI-driven small-molecule discovery and optimization technologies, emphasizing how ChemPass AI™ is enabling new collaborative drug discovery opportunities, potentially fostering partnerships with pharmaceutical and biotech firms.
- Presentation Schedule: Evogene's presentation is scheduled for March 24, 2026, from 15:30 to 15:45, under the theme “Drug Discovery and Development,” which not only showcases the company's technological prowess but may also attract potential investors' interest.
- One-on-One Meeting Opportunities: Both Dr. Tarcic and Dr. Nissan will be available for one-on-one meetings during the conference, encouraging interested parties to contact Evogene's investor or public relations team to facilitate deeper engagement and collaboration.
See More
On-Demand Access to Clean Energy Virtual Investor Conference Presentations
- Conference Replay: Presentations from the March 5, 2026 Clean Energy & Renewables Virtual Investor Conference are now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Management Meeting Requests: Selected companies are accepting one-on-one management meeting requests until March 10, providing investors with direct access to executives, thereby increasing transparency and efficiency in investment decision-making.
- Investor Interaction Platform: Virtual Investor Conferences (VIC) serves as a leading proprietary investor conference series, offering an interactive forum for publicly traded companies to present directly to investors, enhancing the investor experience and optimizing information dissemination.
- Global Investor Network: VIC connects a global network of retail and institutional investors through real-time engagement solutions, further strengthening relationships between companies and investors while increasing market focus on the clean energy sector.
See More
Evogene Ltd. Q4 2025 Earnings Call Insights
- Strategic Transformation: CEO Ofer Haviv emphasized Evogene's deliberate focus on the ChemPass AI engine, concentrating on small molecule drugs and agricultural chemicals to enhance market competitiveness and achieve high-impact business growth.
- Financial Performance: Revenues for 2025 were $3.9 million, down from $5.6 million in 2024, primarily due to reduced AgPlenus activity, with Q4 revenues at only $0.3 million, reflecting challenges in the market.
- Cost Control: Operating expenses for 2025 decreased to approximately $13.8 million from $22 million in 2024, demonstrating the company's effectiveness in financial discipline and cost management.
- Future Outlook: Management anticipates multiple technology collaborations and new drug development agreements over the next 12 months, emphasizing that these partnerships will drive further application of the company's technology and market expansion.
See More
Evogene Reports 2025 Financial Results, Focuses on Core Technology
- Strategic Shift: In 2025, Evogene executed a strategic shift focusing on the ChemPass AI™ technology engine, aiming to enhance the efficiency of small-molecule drug discovery and optimization, thereby strengthening its market competitiveness in pharmaceuticals and agriculture.
- Financial Performance: Evogene reported total revenues of approximately $3.9 million for 2025, a decrease of about $1.7 million from $5.6 million in 2024, primarily due to reduced revenue from AgPlenus activities, reflecting challenges and adjustments in the core markets.
- R&D Expenditure: R&D expenses for 2025 were approximately $8.0 million, down by about $4.5 million from $12.5 million in 2024, indicating the company's optimization in resource allocation aimed at improving R&D efficiency and reducing costs.
- Cash Flow Position: As of December 31, 2025, Evogene held approximately $13.0 million in cash and cash equivalents, with cash usage of about $3.0 million in the fourth quarter, demonstrating a more cautious approach to spending and financial management.
See More
Evogene Reports Q4 Earnings with Significant Revenue Decline
- Earnings Overview: Evogene reported a GAAP EPS of -$0.61 for Q4 2025, indicating significant financial pressure on the company and reflecting a notable decline in profitability.
- Revenue Decline: The revenue for the fourth quarter was $0.31 million, representing a 79.9% year-over-year decrease compared to $1.5 million in the same period last year, highlighting major challenges in market competition.
- Reduced Seed Sales: The revenue drop was primarily due to decreased seed sales generated by Casterra during Q4 2025, which directly impacted the company's overall revenue performance and underscored weak product demand.
- Future Outlook: With such a significant revenue decline, Evogene needs to reassess its market strategies and product lines to address its current financial challenges and seek pathways for recovery and growth.
See More
Evogene Set to Announce Q4 Earnings Results
- Earnings Announcement Date: Evogene is set to release its Q4 earnings on March 5 before market open, with a consensus EPS estimate of -$0.26, reflecting a significant year-over-year decline of 333.3%, indicating substantial profitability challenges.
- Revenue Decline Expectations: The consensus revenue estimate stands at $0.28 million, representing an 82.6% year-over-year decrease, highlighting major challenges in revenue growth that could impact investor confidence moving forward.
- Historical Performance Review: Over the past two years, Evogene has beaten EPS estimates 75% of the time, but only 38% of the time for revenue estimates, indicating considerable volatility in the company's profitability.
- Estimates Revision Dynamics: In the last three months, there has been one upward revision and no downward revisions for EPS estimates, while revenue estimates saw no upward revisions and one downward revision, reflecting a cautious market outlook on the company's future performance.
See More
Evogene to Present at BIO-Europe Spring 2026 Conference
- Conference Appearance: Evogene Ltd. will present at the BIO-Europe Spring 2026 conference in Lisbon, Portugal, from March 23-25, showcasing its latest achievements in the pharma division, which is expected to attract industry attention and enhance the company's visibility.
- Technology Breakthrough Presentation: Chief Development Officer Dr. Gabi Tarcic and VP of Business Development Dr. Olga Nissan will highlight AI-driven small-molecule discovery and optimization technologies, emphasizing how ChemPass AI™ is enabling new collaborative drug discovery opportunities, potentially fostering partnerships with pharmaceutical and biotech firms.
- Presentation Schedule: Evogene's presentation is scheduled for March 24, 2026, from 15:30 to 15:45, under the theme “Drug Discovery and Development,” which not only showcases the company's technological prowess but may also attract potential investors' interest.
- One-on-One Meeting Opportunities: Both Dr. Tarcic and Dr. Nissan will be available for one-on-one meetings during the conference, encouraging interested parties to contact Evogene's investor or public relations team to facilitate deeper engagement and collaboration.
See More
On-Demand Access to Clean Energy Virtual Investor Conference Presentations
- Conference Replay: Presentations from the March 5, 2026 Clean Energy & Renewables Virtual Investor Conference are now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Management Meeting Requests: Selected companies are accepting one-on-one management meeting requests until March 10, providing investors with direct access to executives, thereby increasing transparency and efficiency in investment decision-making.
- Investor Interaction Platform: Virtual Investor Conferences (VIC) serves as a leading proprietary investor conference series, offering an interactive forum for publicly traded companies to present directly to investors, enhancing the investor experience and optimizing information dissemination.
- Global Investor Network: VIC connects a global network of retail and institutional investors through real-time engagement solutions, further strengthening relationships between companies and investors while increasing market focus on the clean energy sector.
See More
Evogene Ltd. Q4 2025 Earnings Call Insights
- Strategic Transformation: CEO Ofer Haviv emphasized Evogene's deliberate focus on the ChemPass AI engine, concentrating on small molecule drugs and agricultural chemicals to enhance market competitiveness and achieve high-impact business growth.
- Financial Performance: Revenues for 2025 were $3.9 million, down from $5.6 million in 2024, primarily due to reduced AgPlenus activity, with Q4 revenues at only $0.3 million, reflecting challenges in the market.
- Cost Control: Operating expenses for 2025 decreased to approximately $13.8 million from $22 million in 2024, demonstrating the company's effectiveness in financial discipline and cost management.
- Future Outlook: Management anticipates multiple technology collaborations and new drug development agreements over the next 12 months, emphasizing that these partnerships will drive further application of the company's technology and market expansion.
See More
Evogene Reports 2025 Financial Results, Focuses on Core Technology
- Strategic Shift: In 2025, Evogene executed a strategic shift focusing on the ChemPass AI™ technology engine, aiming to enhance the efficiency of small-molecule drug discovery and optimization, thereby strengthening its market competitiveness in pharmaceuticals and agriculture.
- Financial Performance: Evogene reported total revenues of approximately $3.9 million for 2025, a decrease of about $1.7 million from $5.6 million in 2024, primarily due to reduced revenue from AgPlenus activities, reflecting challenges and adjustments in the core markets.
- R&D Expenditure: R&D expenses for 2025 were approximately $8.0 million, down by about $4.5 million from $12.5 million in 2024, indicating the company's optimization in resource allocation aimed at improving R&D efficiency and reducing costs.
- Cash Flow Position: As of December 31, 2025, Evogene held approximately $13.0 million in cash and cash equivalents, with cash usage of about $3.0 million in the fourth quarter, demonstrating a more cautious approach to spending and financial management.
See More
Evogene Reports Q4 Earnings with Significant Revenue Decline
- Earnings Overview: Evogene reported a GAAP EPS of -$0.61 for Q4 2025, indicating significant financial pressure on the company and reflecting a notable decline in profitability.
- Revenue Decline: The revenue for the fourth quarter was $0.31 million, representing a 79.9% year-over-year decrease compared to $1.5 million in the same period last year, highlighting major challenges in market competition.
- Reduced Seed Sales: The revenue drop was primarily due to decreased seed sales generated by Casterra during Q4 2025, which directly impacted the company's overall revenue performance and underscored weak product demand.
- Future Outlook: With such a significant revenue decline, Evogene needs to reassess its market strategies and product lines to address its current financial challenges and seek pathways for recovery and growth.
See More
Evogene Set to Announce Q4 Earnings Results
- Earnings Announcement Date: Evogene is set to release its Q4 earnings on March 5 before market open, with a consensus EPS estimate of -$0.26, reflecting a significant year-over-year decline of 333.3%, indicating substantial profitability challenges.
- Revenue Decline Expectations: The consensus revenue estimate stands at $0.28 million, representing an 82.6% year-over-year decrease, highlighting major challenges in revenue growth that could impact investor confidence moving forward.
- Historical Performance Review: Over the past two years, Evogene has beaten EPS estimates 75% of the time, but only 38% of the time for revenue estimates, indicating considerable volatility in the company's profitability.
- Estimates Revision Dynamics: In the last three months, there has been one upward revision and no downward revisions for EPS estimates, while revenue estimates saw no upward revisions and one downward revision, reflecting a cautious market outlook on the company's future performance.
See More
